Monthly
US$200
Billed every month
布洛芬混悬液
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 3 applicationsNo longer listed under review: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders1View records ↓
Under-review filings14View records ↓
This year’s generic filers6View records ↓
NHSA approval numbers46View records ↓
API companies with A status11View records ↓
Chemical-drug catalogue
Loaded records: 1 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| — | 上海强生制药有限公司 | 国药准字H20000359 | 2000/05/23 | 30ml:0.6g | Other drug (其他药品) | CDE |
| — | 上海强生制药有限公司 | 国药准字H19991011 | 1999/03/17 | 100ml:2g | Other drug (其他药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 46 distinct approval numbers and 37 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京韩美药品有限公司 | 国药准字H20084005 | 100ml:2g | Category B (乙) | XM01AEB173X002010100041 | NHSA |
| 广州南新制药有限公司 | 国药准字H20244207 | 100毫升:2克 | Category B (乙) | XM01AEB173X002010100407 | NHSA |
| 天大药业(珠海)有限公司 | 国药准字H10980251 | 30ml:0.6g;60ml:1.2g;100ml:2.0g;120ml:2.4g | Category B (乙) | XM01AEB173X002010100560 | NHSA |
| 上海强生制药有限公司 | 国药准字H19991011 | 100ml:2g | Category B (乙) | XM01AEB173X002010100734 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20255624 | 100ml:2g | Category B (乙) | XM01AEB173X002010100815 | NHSA |
| 葵花药业集团重庆小葵花儿童制药有限公司 | 国药准字H20249373 | 100ml:2g | Category B (乙) | XM01AEB173X002010100972 | NHSA |
| 惠氏制药有限公司 | 国药准字H20020036 | 5ml:0.1g | Category B (乙) | XM01AEB173X002010101421 | NHSA |
| 江苏恒瑞医药股份有限公司 | 国药准字H19980017 | 100ml:2g | Category B (乙) | XM01AEB173X002010101445 | NHSA |
| 济川药业集团有限公司 | 国药准字H20234456 | 100ml:2g | Category B (乙) | XM01AEB173X002010101453 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20249704 | 100ml:2g | Category B (乙) | XM01AEB173X002010101503 | NHSA |
| 扬州市三药制药有限公司 | 国药准字H10970354 | 25ml:0.5g;100ml:2g | Category B (乙) | XM01AEB173X002010101740 | NHSA |
| 扬州一洋制药有限公司 | 国药准字H20103544 | 2% | Category B (乙) | XM01AEB173X002010101742 | NHSA |
| 武汉人福药业有限责任公司 | 国药准字H10980021 | 2% | Category B (乙) | XM01AEB173X002010101958 | NHSA |
| 石家庄凯达生物工程有限公司 | 国药准字H20263745 | 100ml:2g | Category B (乙) | XM01AEB173X002010102680 | NHSA |
| 黑龙江中桂制药有限公司 | 国药准字H20233807 | 100ml:2g | Category B (乙) | XM01AEB173X002010103804 | NHSA |
| 青岛黄海制药有限责任公司 | 国药准字H20254482 | 100ml: 2g | Category B (乙) | XM01AEB173X002010104043 | NHSA |
| 新华制药(高密)有限公司 | 国药准字H20233008 | 100ml:2g | Category B (乙) | XM01AEB173X002010104193 | NHSA |
| 浙江国光生物制药股份有限公司 | 国药准字H20254695 | 100ml:2g | Category B (乙) | XM01AEB173X002010104633 | NHSA |
| 福建太平洋制药有限公司 | 国药准字H20253472 | 100ml:2g | Category B (乙) | XM01AEB173X002010104816 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20264784 | 100ml:2g | Category B (乙) | XM01AEB173X002010104942 | NHSA |
| 广西维威制药有限公司 | 国药准字H20243047 | 100毫升: 2克 | Category B (乙) | XM01AEB173X002010105237 | NHSA |
| 华润三九(南昌)药业有限公司 | 国药准字H20223755 | 100ml:2g | Category B (乙) | XM01AEB173X002010105342 | NHSA |
| 海南斯达制药有限公司 | 国药准字H20244785 | 100ml:2g | Category B (乙) | XM01AEB173X002010105816 | NHSA |
| 湖北多瑞药业有限公司 | 国药准字H20223603 | 100ml:2g | Category B (乙) | XM01AEB173X002010106652 | NHSA |
| 北京诚济制药股份有限公司 | 国药准字H20244754 | 100ml:2g | Category B (乙) | XM01AEB173X002010182209 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20223975 | 100ml:2g | Category B (乙) | XM01AEB173X002010182249 | NHSA |
| 成都倍特得诺药业有限公司 | 国药准字H20255621 | 30ml:0.6g | Category B (乙) | XM01AEB173X002010182338 | NHSA |
| 湖北美思创药业有限公司 | 国药准字H20265689 | 100ml:2g | Category B (乙) | XM01AEB173X002010182874 | NHSA |
| 山东盛迪医药有限公司 | 国药准字H20233143 | 100ml:2g | Category B (乙) | XM01AEB173X002010183086 | NHSA |
| 湖北亨迪药业股份有限公司 | 国药准字H20254440 | 100ml:2g | Category B (乙) | XM01AEB173X002010183405 | NHSA |
| 四川益生智同医药生物科技发展有限公司 | 国药准字H20255815 | 30ml:0.6g | Category B (乙) | XM01AEB173X002010184204 | NHSA |
| 华益药业科技(安徽)有限公司 | 国药准字H20265059 | 100ml:2g | Category B (乙) | XM01AEB173X002010184212 | NHSA |
| 天大医药科技(珠海)有限公司 | 国药准字H20243841 | 100ml:2g | Category B (乙) | XM01AEB173X002010184484 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H10980022 | 2% | Category B (乙) | XM01AEB173X002010201958 | NHSA |
| 天大药业(珠海)有限公司 | 国药准字H10980251 | 30ml:0.6g;60ml:1.2g;100ml:2.0g;120ml:2.4g | Category B (乙) | XM01AEB173X002020100560 | NHSA |
| 上海强生制药有限公司 | 国药准字H20000359 | 30ml:0.6g | Category B (乙) | XM01AEB173X002020100734 | NHSA |
| 湖南状元制药有限公司 | 国药准字H20255619 | 100ml:2g | Category B (乙) | XM01AEB173X002020100815 | NHSA |
| 扬州市三药制药有限公司 | 国药准字H10970354 | 25ml:0.5g;100ml:2g | Category B (乙) | XM01AEB173X002020101740 | NHSA |
| 扬州一洋制药有限公司 | 国药准字H20103544 | 2% | Category B (乙) | XM01AEB173X002020101742 | NHSA |
| 武汉人福药业有限责任公司 | 国药准字H10980021 | 2% | Category B (乙) | XM01AEB173X002020101958 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002020104186 | NHSA |
| 湖北多瑞药业有限公司 | 国药准字H20223603 | 100ml:2g | Category B (乙) | XM01AEB173X002020106652 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20223976 | 30ml:0.6g | Category B (乙) | XM01AEB173X002020182249 | NHSA |
| 成都倍特得诺药业有限公司 | 国药准字H20255622 | 100ml:2g | Category B (乙) | XM01AEB173X002020182338 | NHSA |
| 山东盛迪医药有限公司 | 国药准字H20233142 | 30ml:0.6g | Category B (乙) | XM01AEB173X002020183086 | NHSA |
| 湖北亨迪药业股份有限公司 | 国药准字H20254439 | 30ml:0.6g | Category B (乙) | XM01AEB173X002020183405 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H10980022 | 2% | Category B (乙) | XM01AEB173X002020201958 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002020204186 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H10980022 | 2% | Category B (乙) | XM01AEB173X002020301958 | NHSA |
| 天大药业(珠海)有限公司 | 国药准字H10980251 | 30ml:0.6g;60ml:1.2g;100ml:2.0g;120ml:2.4g | Category B (乙) | XM01AEB173X002030100560 | NHSA |
| 上海强生制药有限公司 | 国药准字H20000359 | 30ml:0.6g | Category B (乙) | XM01AEB173X002030100734 | NHSA |
| 湖南状元制药有限公司 | 国药准字H20255618 | 30ml:0.6g | Category B (乙) | XM01AEB173X002030100815 | NHSA |
| 扬州市三药制药有限公司 | 国药准字H10970354 | 25ml:0.5g;100ml:2g | Category B (乙) | XM01AEB173X002030101740 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H10980022 | 2% | Category B (乙) | XM01AEB173X002030101958 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002030104186 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20223975 | 100ml:2g | Category B (乙) | XM01AEB173X002030182249 | NHSA |
| 山东盛迪医药有限公司 | 国药准字H20247032 | 5毫升:100毫克 | Category B (乙) | XM01AEB173X002030183086 | NHSA |
| 天大药业(珠海)有限公司 | 国药准字H10980251 | 30ml:0.6g;60ml:1.2g;100ml:2.0g;120ml:2.4g | Category B (乙) | XM01AEB173X002030200560 | NHSA |
| 湖南状元制药有限公司 | 国药准字H20255618 | 30ml:0.6g | Category B (乙) | XM01AEB173X002030200815 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002030204186 | NHSA |
| 天大药业(珠海)有限公司 | 国药准字H10980251 | 30ml:0.6g;60ml:1.2g;100ml:2.0g;120ml:2.4g | Category B (乙) | XM01AEB173X002030300560 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002030304186 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002030404186 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002030504186 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002030604186 | NHSA |
| 天大药业(珠海)有限公司 | 国药准字H10980251 | 30ml:0.6g;60ml:1.2g;100ml:2.0g;120ml:2.4g | Category B (乙) | XM01AEB173X002040100560 | NHSA |
| 上海强生制药有限公司 | 国药准字H19991011 | 100ml:2g | Category B (乙) | XM01AEB173X002040100734 | NHSA |
| 湖南状元制药有限公司 | 国药准字H20255618 | 30ml:0.6g | Category B (乙) | XM01AEB173X002040100815 | NHSA |
| 扬州市三药制药有限公司 | 国药准字H10970354 | 25ml:0.5g;100ml:2g | Category B (乙) | XM01AEB173X002040101740 | NHSA |
| 武汉人福药业有限责任公司 | 国药准字H10980021 | 2% | Category B (乙) | XM01AEB173X002040101958 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002040104186 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20223975 | 100ml:2g | Category B (乙) | XM01AEB173X002040182249 | NHSA |
| 天大药业(珠海)有限公司 | 国药准字H10980251 | 30ml:0.6g;60ml:1.2g;100ml:2.0g;120ml:2.4g | Category B (乙) | XM01AEB173X002050100560 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H10980022 | 2% | Category B (乙) | XM01AEB173X002050101958 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002050104186 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20223975 | 100ml:2g | Category B (乙) | XM01AEB173X002050182249 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H10980022 | 2% | Category B (乙) | XM01AEB173X002050201958 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H10980022 | 2% | Category B (乙) | XM01AEB173X002050401958 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H10980022 | 2% | Category B (乙) | XM01AEB173X002050501958 | NHSA |
| 扬州市三药制药有限公司 | 国药准字H10970354 | 25ml:0.5g;100ml:2g | Category B (乙) | XM01AEB173X002060101740 | NHSA |
| 武汉人福药业有限责任公司 | 国药准字H10980021 | 2% | Category B (乙) | XM01AEB173X002060101958 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002060104186 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20223976 | 30ml:0.6g | Category B (乙) | XM01AEB173X002060182249 | NHSA |
| 武汉人福药业有限责任公司 | 国药准字H10980021 | 2% | Category B (乙) | XM01AEB173X002060201958 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002060204186 | NHSA |
| 武汉人福药业有限责任公司 | 国药准字H10980021 | 2% | Category B (乙) | XM01AEB173X002060301958 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H10980022 | 2% | Category B (乙) | XM01AEB173X002060401958 | NHSA |
| 扬州市三药制药有限公司 | 国药准字H10970354 | 25ml:0.5g;100ml:2g | Category B (乙) | XM01AEB173X002070101740 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H10980022 | 2% | Category B (乙) | XM01AEB173X002070101958 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002070104186 | NHSA |
| 海南万玮制药有限公司 | 国药准字H20223976 | 30ml:0.6g | Category B (乙) | XM01AEB173X002070182249 | NHSA |
| 武汉九珑医药有限责任公司 | 国药准字H20256118 | 100ml:2g | Category B (乙) | XM01AEB173X002080101958 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20030648 | 5ml:0.1g | Category B (乙) | XM01AEB173X002080104186 | NHSA |
| 武汉九珑医药有限责任公司 | 国药准字H20263238 | 30ml:0.6g | Category B (乙) | XM01AEB173X002090101958 | NHSA |
| 翔宇药业股份有限公司 | 国药准字H20258282 | 100ml:2g | Category B (乙) | XM01AEB173X002090104186 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 14 filings and 12 distinct first applicants.
Generic 11 · Supplement 2 · Import 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 珠海联邦制药股份有限公司 | CYHS2602380 | Generic | 2026/09/22 | Not stated by source | CDE |
| 上海强生制药有限公司 | CYHB2601768 | Supplement | 2026/09/20 | Not stated by source | CDE |
| 上海强生制药有限公司 | CYHB2601767 | Supplement | 2026/09/20 | Not stated by source | CDE |
| 河南羚锐制药股份有限公司 | CYHS2601191 | Generic | 2026/05/22 | Not stated by source | CDE |
| 国药控股星鲨制药（厦门）有限公司 | CYHS2600817 | Generic | 2026/04/09 | Not stated by source | CDE |
| 国药控股星鲨制药（厦门）有限公司 | CYHS2600816 | Generic | 2026/04/09 | Not stated by source | CDE |
| 云鹏医药集团有限公司 | CYHS2600790 | Generic | 2026/04/08 | Not stated by source | CDE |
| 黑龙江诺捷制药有限责任公司 | CYHS2600373 | Generic | 2026/02/05 | Not stated by source | CDE |
| 吉林省益浦生物科技有限公司 | CYHS2600355 | Generic | 2026/02/04 | Not stated by source | CDE |
| 健民药业集团股份有限公司;健民集团叶开泰国药(随州)有限公司 | CYHS2504118 | Generic | 2025/12/02 | Not stated by source | CDE |
| 浙江迪耳药业有限公司 | CYHS2503684 | Generic | 2025/10/15 | Not stated by source | CDE |
| BRIGHT FUTURE PHARMACEUTICAL LABORATORIES LIMITED;BRIGHT FUTURE PHARMACEUTICALS FACTORY | JYHS2500043 | Import | 2025/09/29 | Not stated by source | CDE |
| 亚宝药业四川制药有限公司 | CYHS2502297 | Generic | 2025/06/27 | Not stated by source | CDE |
| 中山可可康制药有限公司 | CYHS2502106 | Generic | 2025/06/12 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 7 filings and 6 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 珠海联邦制药股份有限公司 | CYHS2602380 | Generic | 2026/09/22 | Not stated by source | CDE |
| 河南羚锐制药股份有限公司 | CYHS2601191 | Generic | 2026/05/22 | Not stated by source | CDE |
| 国药控股星鲨制药（厦门）有限公司 | CYHS2600817 | Generic | 2026/04/09 | Not stated by source | CDE |
| 国药控股星鲨制药（厦门）有限公司 | CYHS2600816 | Generic | 2026/04/09 | Not stated by source | CDE |
| 云鹏医药集团有限公司 | CYHS2600790 | Generic | 2026/04/08 | Not stated by source | CDE |
| 黑龙江诺捷制药有限责任公司 | CYHS2600373 | Generic | 2026/02/05 | Not stated by source | CDE |
| 吉林省益浦生物科技有限公司 | CYHS2600355 | Generic | 2026/02/04 | Not stated by source | CDE |
API registrations
Non-component matches: 11 companies with A status and 2 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 布洛芬 | 云鹏医药集团有限公司 | Y20260000554 | I | Exact ingredient | 2026/07/23 | CDE |
| 布洛芬 | SMS Pharmaceutical Limited | Y20230001192 | I | Exact ingredient | 2024/01/09 | CDE |
| 布洛芬 | 仁和堂药业有限公司 | Y20210001112 | A | Exact ingredient | 2025/06/03 | CDE |
| 布洛芬 | IOL Chemicals and Pharmaceuticals Ltd. | Y20220000857 | A | Exact ingredient | 2025/02/26 | CDE |
| 布洛芬 | SOLARA ACTIVE PHARMA SCIENCES LIMITED | Y20210000499 | A | Exact ingredient | 2023/03/24 | CDE |
| 布洛芬 | 珠海润都制药股份有限公司 | Y20210000195 | A | Exact ingredient | 2026/06/18 | CDE |
| 布洛芬 | 山东新华制药股份有限公司 | Y20190009435 | A | Exact ingredient | — | CDE |
| 布洛芬 | 湖北亨迪药业股份有限公司 | Y20190008553 | A | Exact ingredient | 2025/08/27 | CDE |
| 布洛芬 | 华东医药（西安）博华制药有限公司 | Y20190006681 | A | Exact ingredient | — | CDE |
| 布洛芬 | 好医生药业集团有限公司 | Y20190005969 | A | Exact ingredient | — | CDE |
| 布洛芬 | 台山市新宁制药有限公司 | Y20190003234 | A | Exact ingredient | 2026/02/28 | CDE |
| 布洛芬 | 华中药业股份有限公司 | Y20190003113 | A | Exact ingredient | 2025/06/11 | CDE |
| 布洛芬 | 淄博新华-百利高制药有限责任公司 | Y20190002336 | A | Exact ingredient | 2024/07/27 | CDE |
| 布洛芬 | 山东新华制药股份有限公司 | Y20180001074 | A | Exact ingredient | 2024/09/04 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/23No longer listed under review
山西同达药业有限公司
CYHS2500536
Fact date: 2026/10/23 · Site observation date: 2026/10/23
Accepted: 2025/01/27
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/09/22Accepted
-
2026/09/20Accepted
-
2026/09/20Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to this drug
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy